Risperidone: A novel antipsychotic with many 'atypical' properties?

Psychopharmacology

Volumn 127, Issue 3, 1996, Pages 181-186

  Stathis, Pantelis ^a   Antoniou, Katerina ^a   Papadopoulou Daifotis, Z ^a   Rimikis, Michael N ^b   Varonos, Dionisios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Research and Development Department Ellinogermaniki Agogi   (Greece)

Author keywords

5HT; DA; Dorsal striatum; Haloperidol; Nucleus accumbens; Prefrontal cortex; Risperidone; Turnover rate

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; HOMOVANILLIC ACID; NEUROLEPTIC AGENT; NEW DRUG; RISPERIDONE; SEROTONIN; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; TURNOVER TIME;

EID: 0029806529     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246125     Document Type: Article

References (46)

1. Anden NE, Grenhoff J, Svensson TH (1988) Does treatment with haloperidol for 3 weeks produce depolarization block in midbrain dopamine neurons of unanaesthetized rats. Psychopharmacology 96:558-560
2. Arnt J (1982) Pharmacological specificity of conditioned avoidance responce inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacolo Toxicol 51:321
3. Bacopoulos NC, Spokes EG, Bird ED, Roth RH (1979) Antipsychotic drug action in schizophrenic patients: effects on cortical dopamine metabolism after long-term treatment. Science 205:1405-1407
4. Bannon MJ, Roth RH (1983) Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 35 [1]:53-68
5. Blaha CD, Lane RF (1984) Direct in vivo electrochemical monitoring of dopamine release in response to neuroleptic drugs. Eur J Pharmacol 98:113-119
6. Blaha CD, Lane FR (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and n. accumbens in vivo. Neurosci Lett 78:199-204
7. Bowers MB Hoffman FJ (1986) Homovanillic acid in caudate and prefrontal cortex following acute and chronic neuroleptic administration. Psychopharmacology 88:63-65
8. Bunney BS, Chiodo LA (1984) Mesocortical dopamine systems: further electrophysiological and pharmacological characteristics. In: Monoamine innervation of cerebral cortex. Alan R. Liss, New York, pp 263-277
9. Carli M, Jones G.H, Robbins TW (1989) Effects of unilateral dorsal and ventral striatal dopamine derlation on visual neglect in the rat: a neural and behavioural analysis. Neuroscience 29 [2]: 309-327
10. Chen J, Paredes W, Gardner EL (1991) Chronic treatment with clozapine selectively decreases basal dopamine release in n. accumbens but not in caudate-putamen as measured by in vivo brain microdialysis: further evidence for depolarization block. Neurosci Lett 122:127-131
11. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effect of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607-1619
12. Chouinard G, Arnott W (1993) Clinical revew of risperidone. Can J Psychol 38 [Suppl. 3]:89-95
13. Cooper JR, Bloom FE, Roth RH (1991) The biochemical basis of neuropharmacology, 6th edn. Oxford University Press, Oxford
14. Costall B, Naylor RJ (1976) A comparizon of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonize the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Eur J Pharmacol 40:9
15. Deutch AY (1992) The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm 36:61-89
16. Di Giulio AM, Groppettia A, Cattabeni F, Galli CL, Maggi A, Algeri S, Ponzio F (1978) Significance of dopamine metabolites in the evaluation of drugs acting on dopaminergic neurons. Eur J Pharmacol 52:201-207
17. Ereshefsky L, Lacombe S (1993) Pharmacological profile of risperidone. Can J Psychiatry 38 [Suppl. 3]:80-88
18. Grace A A (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizoprenia. Neuroscience 41[1]:1-24
19. Grace AA (1992) The depolarization block hypothesis of neuroleptic action implications for the etiology and treatment of schizophrenia. J Neural Transm 36:91-131
20. Grace AA (1993) Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm 91:111-134
21. Hernandez L, Hoebel BG (1989) Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res Bull 22:763-769
22. Ichikawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and nucleus accumbens. J Pharmacol Exp Ther 256:348-357
23. Imperato A, Di Chiara G (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci 5:297-306
24. 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460:398-401
25. Learner, P, Nose P (1977) Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover. Science 19:181-183
26. Leysen JE, Gommeren W, Eens A, Chaffoy de Courcelles D, Stoof JC. Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
27. Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels P, Janssen PAJ (1991) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocapcridone. Mol Pharmacol 41:494-508
28. 2 receptors. Psychopharmacology 112:s40-s54
29. Mefford IN, Roth KA, Agren H, Barchas JD (1988) Enhancement of dopamine metabolism in rat brain frontal cortex: a common effect of chronically administered antipsychotic drugs. Brain Res 475:380-384
30. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17 [2]:263-287
31. Nomikos GG, Iurlo M, Anderson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147-156
32. Nomikos GG, Hertel P, Markus M, Iurlo M, Svensson TH (1995) Selective action of risperidone on serotonin but not dopamine metabolism in the rat prefrontal cortex. Workshop: critical issues in the treatment of schizophrenia campaign on schizophrena. Abstract book, pp 183-184
33. Pehek EA, Meltzer HY, Yamamoto BK (1993a) Local administration of ritanserin or ICS 205.930 enhances dopamine and serotonin efflux in rat prefrontal cortex. Soc Neurosci Abstr 19:302
34. Pehek EA, Meltzer HY, Yamamoto BK (1993b) The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 240: 107-111
35. Reynolds, GP (1992) Developments in the drug treatment of schizophrenia. Trends Pharmocol Sci 13:116-121
36. Roth RH (1983) Neuroleptics:functional neurochemistry. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven, New York, pp 119-156
37. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279
38. Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993) Occupancy of central neurotransmitter receptors by risperidone. clozapine and haloperidole, measured ex vivo by quantitative autoradiography. Brain Res 631: 191-202
39. Seeman P (1995) Dopamine receptors. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York
40. Sharp T, Zetterstrom T, Series H G, Carlsson A, Graham E, Smith DG, Ungerstedt U (1987) HPLC-EC analysis of catechols and indoles in rat brain dialysates. Life Sci 41:869-872
41. Skarsfelt T (1988) Differential effects after repeated treatment with haloperidol, lozapine, thioridazine and lefludazine on SNc and VTA dopamine neurons in rats. Life Sci 42:1037-1044
42. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D (1974) Drugs neurotransmitters and schizophrenia. Science 184:1243-1253
43. Westerink BHC (1979) The effects of drugs on dopamine biosynthesis and metabolism in the brain. In: Horn AS, Korf J, Westering BHS (eds) The neurobiology of dopamine. Academic Press, London, pp 251-290
44. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057
45. White FJ Wang RY (1982) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 32:983-993
46. Zetterstrom T, Sharp T, Ugerstedt U (1985) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106:27-37